François Ravenelle, PhD Appointed President and CEO of Innospera Pharma to Lead Next Phase of Growth
MONTREAL--(BUSINESS WIRE)-- Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company focused on developing small-molecule modulators of GPR84 and GPR40 to address a broad range of inflammatory and metabolic diseases with high unmet medical needs, today announced the appointment of François Ravenelle, PhD, as President and Chief Executive Officer, effective immediately.
"With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions." - François Ravenelle
Share
Dr. Ravenelle is an accomplished biotech leader with over two decades of experience in pharmaceutical R&D and executive management. He most recently served as President and CEO of Inversago Pharma, a clinical-stage company developing therapies based on peripheral CB1 receptor blockade to treat metabolic and fibrotic diseases. Under his leadership, Inversago raised more than $100M, and was acquired by Novo Nordisk for up to approximately $1 billion USD.
'I'm thrilled to join Innospera at this pivotal stage, as the company moves toward clinical development with a lead asset that shows strong potential for an exceptional balance of safety and efficacy in targeting inflammatory and metabolic pathways,' said Dr. Ravenelle. 'With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions. I'm excited to contribute to the company's next phase of growth.'
Pierre Laurin, Executive Chairman of the Board, founder and former CEO, commented: 'François' appointment comes at the perfect time following the completion of our seed financing round. His proven leadership and strategic vision will be invaluable as we prepare for clinical development and beyond. Investissement Québec, Seido Capital, and Anges Québec worked synergistically together to support Innospera's vision, based on the strong potential of our lead assets. We are privileged to work in one of the best life science clusters in North America, where innovation is recognized by quality investors, acting together as catalysts for promising endeavours like ours.'
About Long-term Inflammation
Systemic inflammation (inflammaging), increases as a consequence of aging contributing to age-related morbidities. Persistent activation of fibrotic pathways and organ dysfunction is markedly more frequent in the elderly (fibroaging). Elderly individuals with chronic disorders tend to develop inflammaging, a condition associated with elevated levels of blood inflammatory markers and increased susceptibility to chronic disease progression. Chronic, low-grade inflammation is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the lung, kidney, heart, liver, nervous and the musculoskeletal system.
About Innospera
Innospera is a privately-owned biotech company near clinical stage, developing small molecule modulators of 7-transmembrane receptors involved in a broad range of chronic and fibrotic conditions. The company's lead drug candidates target key G-protein coupled receptors (GPCR) involved in fibroaging and inflammaging, including idiopathic pulmonary fibrosis (IPF), a condition with dire short-term prognosis. Innospera also develops multiple other modulators with promising potency in other medical conditions with pressing unmet needs. For more information, visit innospera.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Sobot Reveals "AI-First" Strategy for Delivering Human-like Customer Service
Reshaping AI-Powered Customer Service and CX with Five Pillars of Next-Gen AI NEW YORK, June 10, 2025 /PRNewswire/ -- Sobot, a leading AI customer contact solution provider, unveiled its "AI-First" strategy at a media launch event this month. The move elevates Sobot AI with five pillars, including Omnichannel AI, Scenario-Based AI, Multi-Faceted AI, Generative AI and Secure AI to create an experience-led, easy-to-use, and efficiency-driven solution. Sobot Aims to Deliver Intelligent yet More Human-like Service AI has quickly become central to digital transformation in customer service. According to MarketsandMarkets, the global AI-for-customer-service market was valued at USD 12.06 billion in 2024 and is projected to reach USD 47.82 billion by 2030. Yet 52% of customers prefer human interaction for its empathy, while another 42% favor a blend of AI and human support. While some customers find AI insufficiently human, its adoption in customer service is now irreversible. Customer service solution providers must therefore balance customer expectations with the power of AI. "Fed up with limited contextual comprehension, inflexible responses, and poor emotional perception, customers want their needs understood and met," said Yi Xu, CEO of Sobot. "Our 'AI-First' strategy doesn't just automate processes; it aims to provide intelligent but more human-like services." Highlight of Sobot's AI-First Strategy: Five Pillars of Next-Gen AI Omnichannel AI - Ensuring Seamless, Efficient Experience Across All Channels Sobot AI integrates websites, mobile apps, social platforms such as Facebook, Instagram and WhatsApp, plus email, phone calls and SMS. Beyond online chat, it includes AI voicebot that can handle inbound and outbound calls. Sobot AI also unifies and connects information of all channels, giving customers a seamless experience wherever they start. Scenario-Based AI - Providing Industry-Specific Solutions Sobot AI is never limited to fixed functions, it keeps upgrading and extending, making it suitable for various industries. Designed especially for retail and e-commerce, Sobot AI spans the entire purchase journey. It answers pre-sales inquiries 24/7, converting browsers into buyers; it sends personalized recommendations during checkout to increase the sales volume; it resolves post-sales issues quickly to boost customer satisfaction. Multi-Faceted AI - Supporting Customers, Agents and Administrators Sobot AI supports multiple roles during the process of customer service. For customers, Sobot AI Agent learns from the knowledge base to deliver accurate, humanized service. For human agents, Sobot AI Copilot suggests replies and drafts summaries, raising efficiency. For administrators, Sobot AI Insight supplies detailed dashboards to optimize operations. Generative AI - Combining Multiple Advanced LLMs and SLMs Powered by leading LLMs (Large Language Models) such as OpenAI and DeepSeek, Sobot AI boasts powerful generative capacity able to decompose knowledge, retrieve the most relevant content, and intelligently composes accurate responses. Sobot AI is also powered by several SLMs (Small Language Models), which is helpful to create industry-oriented solutions, enhancing the accuracy and professionalism of customer service. Secure AI - Guaranteeing Global Data Privacy and Compliance Sobot aligns its platform with country-specific regulations and holds a number of internationally recognized certifications in information, cloud, and system security. Regional data centers in the United States, Europe, Singapore, and other locations ensure reliable performance worldwide. Sobot is Committed to Reshaping Customer Service with Humanized AI Alongside its "AI-First" strategy, Sobot has refreshed its website, especially the AI Solution page so customers can easily learn more about the basic features, use cases, benefits, and more of Sobot AI. And just as what is shown in its website, Sobot's new generation of AI is committed to creating "experience-led, easy-to-use and efficiency-driven AI for CX". Xu added, "Our strategy prioritizes customer experience, but it is equally valuable for businesses. The five pillars are its cornerstone, yet their essence is humanization. Sobot will continue to practice this vision, helping more customers and companies reshape service through humanized AI." For more information, please visit View original content to download multimedia: SOURCE Sobot Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
REDWOOD CITY, Calif., June 09, 2025--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. "The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever," said Olivier Lauzeral, General Manager of Somnics Health. "With iNAP Essentials, we're removing the affordability hurdle." A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. "Adherence is one of iNAP's biggest strengths," added Lauzeral. "When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA." What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. "We built this program with transparency and simplicity at its core," said Lauzeral. "It's everything you need to start treatment—nothing you don't." Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. "Some patients want to purchase the device outright. With Affirm, they can do that without financial strain," said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. "Physicians are seeing the value of iNAP in improving adherence and patient satisfaction," Lauzeral emphasized. "When patients feel empowered, they stay engaged—and that's the future of sleep medicine." Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. "This isn't just about access—it's about fairness," said Lauzeral. "Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health." About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence. Learn More: View source version on Contacts Press Contact: Olivier Lauzeral – olivier@ Follow us on: LinkedIn | Facebook | YouTube Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Wall Street Journal
2 hours ago
- Wall Street Journal
Asian Currencies Consolidate Amid U.S.-China Trade Talks
0033 GMT — Asian currencies consolidate against the dollar in early trade amid U.S.-China trade talks in London. The main theme has been consolidation, Commerzbank Research analysts say in a report. Both sides will continue their negotiations for a second day today, they say. Commerce Secretary Lutnick said the talks were 'fruitful,' while Treasury Secretary Bessent said it was a 'good meeting' and 'we are doing well with China,' the analysts note. USD/JPY edges 0.1% lower to 144.42, USD/KRW is little changed at 1,354.75, and USD/MYR is 0.1% higher at 4.2357, FactSet data show. (
